STAT to host three-day, virtual 'Future Summit' September 5-7
/PRNewswire/ -- STAT, the leading media company reporting on health, science, and medicine, is proud to host its inaugural STAT Future Summit next week, Sept....
Stay updated with breaking news from Ruth Karron. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- STAT, the leading media company reporting on health, science, and medicine, is proud to host its inaugural STAT Future Summit next week, Sept....
A monoclonal antibody will be offered this fall to prevent respiratory syncytial virus in children. If antibodies are a viable vaccine alternative for kids, will we see new options for adults too?
There are sizable hurdles standing in the way of the implementation of both a new vaccine and a monoclonal antibody.
The FDA approved the first RSV vaccine Wednesday, called Arexvy, which is designed to be given as a single shot to adults 60 and over.
The FDA has approved the first-ever vaccine designed to protect against respiratory syncytial virus (RSV), a development 60 years in the making.